Raymond James: 'WVE regains full economic rights to WVE-006 from GSK'
Tweet Send to a Friend
Raymond James analyst Michael Freeman reiterated an Outperform rating and $26.00 price target on WAVE Life Sciences (NASDAQ: WVE).The analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
